297 related articles for article (PubMed ID: 30237211)
1.
Ulaner GA; Juarez J; Riedl CC; Goldman DA
J Nucl Med; 2019 Apr; 60(4):472-477. PubMed ID: 30237211
[No Abstract] [Full Text] [Related]
2.
Ulaner GA; Castillo R; Wills J; Gönen M; Goldman DA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1420-1427. PubMed ID: 28456837
[TBL] [Abstract][Full Text] [Related]
3. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.
Hogan MP; Goldman DA; Dashevsky B; Riedl CC; Gönen M; Osborne JR; Jochelson M; Hudis C; Morrow M; Ulaner GA
J Nucl Med; 2015 Nov; 56(11):1674-80. PubMed ID: 26294295
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years.
Riedl CC; Slobod E; Jochelson M; Morrow M; Goldman DA; Gonen M; Weber WA; Ulaner GA
J Nucl Med; 2014 Oct; 55(10):1578-83. PubMed ID: 25214641
[TBL] [Abstract][Full Text] [Related]
6. Whole-body
Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
[TBL] [Abstract][Full Text] [Related]
7. Rate of Distant Metastases on 18F-FDG PET/CT at Initial Staging of Breast Cancer: Comparison of Women Younger and Older Than 40 Years.
Lebon V; Alberini JL; Pierga JY; Diéras V; Jehanno N; Wartski M
J Nucl Med; 2017 Feb; 58(2):252-257. PubMed ID: 27587709
[TBL] [Abstract][Full Text] [Related]
8. Do 18F-FDG PET/CT findings have a relationship with histopathological and immunohistochemical factors of breast cancer in men?
Vatankulu B; Işik G; Kocael P; Kuyumcu S; Ilvan Ş; Sağer S; Halaç M; Türkmen C; Sönmezoğlu K
Nucl Med Commun; 2016 Dec; 37(12):1273-1281. PubMed ID: 27472037
[TBL] [Abstract][Full Text] [Related]
9. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
Groheux D; Hindié E; Marty M; Espié M; Rubello D; Vercellino L; Bousquet G; Ohnona J; Toubert ME; Merlet P; Misset JL
Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086
[TBL] [Abstract][Full Text] [Related]
10.
Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z
Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of 18F-FDG PET/CT in low 18F-FDG-avidity breast cancer subtypes: comparison with breast US and MRI.
Park HL; Yoo IR; O JH; Kim H; Kim SH; Kang BJ
Nucl Med Commun; 2018 Jan; 39(1):35-43. PubMed ID: 28984814
[TBL] [Abstract][Full Text] [Related]
12. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers.
Ulaner GA; Goldman DA; Gönen M; Pham H; Castillo R; Lyashchenko SK; Lewis JS; Dang C
J Nucl Med; 2016 Sep; 57(9):1350-6. PubMed ID: 26940766
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Performance of F18-FDG PET/CT in Male Breast Cancers Patients.
Piciu A; Piciu D; Polocoser N; Kovendi AA; Almasan I; Mester A; Morariu DS; Cainap C; Cainap SS
Diagnostics (Basel); 2021 Jan; 11(1):. PubMed ID: 33451072
[TBL] [Abstract][Full Text] [Related]
14. The role of FDG PET/CT in detection of distant metastasis in theinitial staging of breast cancer.
Aliyev A; Yilmaz Aksoy S; Özhan M; Ekmekçioğlu Ö; Vatankulu B; Kocael PÇ; Sağer MS; Erkan ME; Sönmezoğlu K; Halaç M
Turk J Med Sci; 2016 Feb; 46(2):349-60. PubMed ID: 27511496
[TBL] [Abstract][Full Text] [Related]
15. Routinely staging gastric cancer with
Findlay JM; Antonowicz S; Segaran A; El Kafsi J; Zhang A; Bradley KM; Gillies RS; Maynard ND; Middleton MR
Eur Radiol; 2019 May; 29(5):2490-2498. PubMed ID: 30643947
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer staging in a single session: whole-body PET/CT mammography.
Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.
Groheux D; Hindié E; Delord M; Giacchetti S; Hamy AS; de Bazelaire C; de Roquancourt A; Vercellino L; Toubert ME; Merlet P; Espié M
J Natl Cancer Inst; 2012 Dec; 104(24):1879-87. PubMed ID: 23243198
[TBL] [Abstract][Full Text] [Related]
18. The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study.
Groheux D; Giacchetti S; Espié M; Vercellino L; Hamy AS; Delord M; Berenger N; Toubert ME; Misset JL; Hindié E
J Nucl Med; 2011 Oct; 52(10):1526-34. PubMed ID: 21880576
[TBL] [Abstract][Full Text] [Related]
19. Role of 18F-FDG PET/CT in identifying distant metastatic disease missed by conventional imaging in patients with locally advanced breast cancer.
Manohar K; Mittal BR; Bhoil A; Bhattacharya A; Singh G
Nucl Med Commun; 2013 Jun; 34(6):557-61. PubMed ID: 23549551
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and Prognostic Value of 18F-FDG PET/CT in Male Breast Cancer: Results From a Bicentric Population.
Evangelista L; Bertagna F; Bertoli M; Stela T; Saladini G; Giubbini R
Curr Radiopharm; 2016; 9(2):169-77. PubMed ID: 26018128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
